Skip to content

Lipid Characterisation of Plasma Microparticles in a Large Population of Healthy Donors

Lipid Characterisation of Plasma Microparticles in a Large Population of Healthy Donors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06183632
Acronym
MicroLipids
Enrollment
150
Registered
2023-12-27
Start date
2024-01-25
Completion date
2029-01-31
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Donor

Brief summary

Extracellular vesicles (EVs) are membrane structures containing numerous mediators categorised according to their size and mode of production. Among them, microparticles (MPs) are EVs between 100 nm and 1 μm in size that are produced by budding at the plasma membrane of different cell types following different mechanisms of cell activation or death. MPs include a large pool of bioactive molecules, such as lipids, proteins or nucleic acids. This makes them important mediators of intercellular communication, increasingly recognised for their role in various biological processes such as inflammation, coagulation, immune response and tumour progression. Their ability to transmit molecular signals between cells may have implications for disease pathogenesis and cellular interactions in pathological microenvironments. These MPs therefore appear to be an innovative biomarker, potentially useful in the early management of disease, both in terms of diagnosis and as a therapeutic target. The main techniques used to analyse these MPs include flow cytometry, which enables surface markers to be quantified and determined, and electron microscopy, which provides a direct view of their morphology and structure. Molecular biology, such as the quantitative PCR technique, is also an approach used by several teams, notably to search for RNA or DNA fragments involved in various biological processes. However, few studies have focused on the lipid composition of these MPs. Since MPs are membrane vesicles, they are a major lipid reservoir. In addition, lipids represent a significant population of molecules with extensive properties, whether in inflammation, cell proliferation, energy metabolism, etc. The aim of this project is to develop a reliable and robust method for analysing plasma MP concentration, phenotype and lipid composition in a population of healthy volunteers. These parameters will subsequently provide a comparator for studying MPs in populations of patients suffering from cardiovascular and/or inflammatory diseases.

Interventions

BIOLOGICALblood sampling

3 x 7mL EDTA blood tubes

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Person who has given his/her non-opposition * All healthy volunteers are eligible to donate according to EFS criteria.

Exclusion criteria

* Person subject to a legal protection measure (curatorship, guardianship, etc) * Pregnant, parturient or breast-feeding women * Adults who are incapable or unable to give their consent * Minors * Person not eligible to donate according to EFS criteria.

Design outcomes

Primary

MeasureTime frame
microparticle concentration, phenotyping and lipid composition in a population of healthy subjects.Through study completion, an average of 60 months

Countries

France

Contacts

Primary ContactDamien LELEU
Damien.leleu@chu-dijon.fr0380669248

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026